Paeoniflorin Modulates Tmem176b+ Macrophages in Hepatic Ischemia-Reperfusion Injury

Study Background and Research Question

Hepatic ischemia-reperfusion (I/R) injury is a critical challenge during liver transplantation and major hepatic resections, often leading to early allograft dysfunction and poor graft survival. While the multifaceted pathogenesis of I/R injury includes oxidative stress, cytokine storms, and immune activation, mounting evidence highlights the pivotal role of macrophage polarization—particularly the M1 (pro-inflammatory) and M2 (reparative) states—in dictating tissue outcomes. Despite the therapeutic potential of immunomodulation, precise strategies to mitigate macrophage-driven injury remain limited. Paeoniflorin (PF), a bioactive compound widely used in traditional Chinese medicine, is known for its hepatoprotective and immune-modulating properties, but its specific effects on hepatic macrophage subpopulations during I/R injury were previously unclear. This study addresses the central question: can PF modulate specific macrophage subsets to attenuate hepatic I/R injury, and through what molecular mechanisms?

Key Innovation from the Reference Study

The primary innovation of Tang et al.'s work lies in the application of high-resolution single-cell RNA sequencing (scRNA-seq) to dissect hepatic immune cell populations following I/R injury and PF treatment. By focusing on Tmem176b+ macrophages—a previously underexplored subset—the authors demonstrate that PF's hepatoprotective effects are mediated through targeted modulation of macrophage polarization. Notably, the study identifies an immunoregulatory axis (THBS1-CD47 upregulation and SPP1-CD44 suppression) as a mechanistic pathway by which PF enforces a shift from inflammatory to reparative phenotypes within the hepatic macrophage compartment (reference study).

Methods and Experimental Design Insights

The research employed a robust suite of experimental approaches:

• In vivo hepatic I/R mouse model: Mice underwent partial hepatic ischemia followed by reperfusion, with groups receiving PF or vehicle.
• Single-cell RNA sequencing: 45,673 hepatic cells from PF-treated and control mice were profiled to resolve immune subpopulations and transcriptional changes associated with injury and treatment.
• Bioinformatics analyses: Differential gene expression, pseudotime trajectory, and cell-cell interaction analyses elucidated macrophage subset transitions and pathway engagement.
• Functional validation: Selective depletion of Tmem176b+ macrophages using a TMEM176B inhibitor clarified their essential role in mediating PF's protective effects.
• Biochemical and histological assays: Serum ALT/AST levels, histopathology (necrosis and apoptosis), and qPCR for inflammatory markers provided phenotypic correlates.

Of note, the study utilized clodronate liposomes as a positive control for in vivo macrophage depletion, leveraging their established utility in immune cell modulation and mechanistic dissection (internal article).

Protocol Parameters

• Hepatic I/R induction: Partial hepatic ischemia for a defined duration (typically 60 minutes), followed by reperfusion in anesthetized mice.
• Paeoniflorin administration: Intraperitoneal injection at 20 mg/kg one hour prior to ischemia, based on dose optimization in preliminary experiments.
• Macrophage depletion (positive control): Intravenous injection of clodronate liposomes (200 μL per 20–25 g mouse) 24 hours prior to I/R surgery, to achieve systemic in vivo macrophage depletion.
• Tissue and serum collection: Harvest at 6 and 24 hours post-reperfusion for downstream analyses.

Core Findings and Why They Matter

PF treatment significantly attenuated hepatic injury, as reflected by reduced serum ALT/AST, decreased necrotic area, and suppression of apoptosis compared to vehicle controls. Single-cell analysis revealed that PF selectively modulated macrophage subpopulations, driving a pronounced shift from M1-like (inflammatory) to M2-like (reparative) phenotypes. Pseudotime trajectory mapping illustrated that PF facilitated the conversion of inflammatory macrophages toward a reparative state, with the transition particularly marked in Tmem176b+ cells.

Functional depletion of Tmem176b+ macrophages abrogated PF’s protective effect, underscoring their necessity. Mechanistically, PF upregulated the immunosuppressive THBS1-CD47 axis—associated with anti-inflammatory signaling—while downregulating the SPP1-CD44 pathway that promotes pro-inflammatory responses. These findings elucidate a previously unrecognized cellular and molecular target for intervention in hepatic I/R injury (reference study).

Comparison with Existing Internal Articles

The use of clodronate liposomes for in vivo macrophage depletion is well-documented in immunology research. Internal articles such as "Clodronate Liposomes: Precision Macrophage Depletion Reagent" and "Clodronate Liposomes (K2721): Data-Driven Macrophage Depl..." detail the reagent’s advantages for selective, reproducible ablation of macrophages via phagocytosis-mediated drug delivery and apoptosis induction. In the reference study, clodronate liposomes served as a benchmark for evaluating the necessity of specific macrophage subsets in the context of immune cell modulation and injury modeling. This aligns with broader literature on the utility of liposome-encapsulated clodronate in dissecting macrophage function across diverse pathophysiological models.

Limitations and Transferability

While the study provides compelling evidence for the immunomodulatory effects of PF via Tmem176b+ macrophages, several limitations warrant consideration. The translational potential of targeting Tmem176b+ cells in human liver transplantation remains to be validated, as mouse models may not fully recapitulate human immune complexity. Additionally, the focus on a single macrophage subset and defined signaling axes, while mechanistically illuminating, does not exclude the contribution of other immune or stromal cell populations. The specificity of PF's action in other organs or injury settings also requires further study.

Research Support Resources

For researchers aiming to interrogate the role of macrophages in hepatic or other tissue injury models, Clodronate Liposomes (SKU K2721, APExBIO) offer a validated approach for in vivo macrophage depletion. These liposomes leverage phagocytosis-mediated delivery to induce apoptosis selectively in macrophages, enabling precise immune cell modulation in mechanistic and disease modeling workflows. Their compatibility with various administration routes and transgenic models supports broad experimental flexibility. For protocol optimization and reproducible results, PBS Liposomes are recommended as controls.